Benzinga · Aug 4, 2026
UBS Maintains Buy on SI-BONE, Raises Price Target to $25
UBS analyst Patrick Wood maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $24 to $25.
NASDAQ · SIBN
Healthcare · Medical - Devices
$18.50
Down-$0.14 (-0.75%)
Updated Sep 7, 2026, 7:29 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SIBN closed at $18.50 after 20 trading sessions, down 1.80% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $18.50 | $18.7466 | $18.195 | $18.50 | 389.53K |
| Sep 3, 2026 | $19.45 | $19.65 | $18.55 | $18.64 | 632.45K |
| Sep 2, 2026 | $18.92 | $19.715 | $18.92 | $19.16 | 786.85K |
| Sep 1, 2026 | $19.12 | $19.46 | $18.62 | $18.92 | 561.08K |
| Aug 31, 2026 | $19.01 | $19.17 | $18.81 | $19.02 | 301.89K |
| Aug 28, 2026 | $19.38 | $19.61 | $19.14 | $19.21 | 361.13K |
| Aug 27, 2026 | $19.40 | $19.68 | $19.17 | $19.20 | 629.38K |
| Aug 26, 2026 | $19.50 | $19.95 | $19.24 | $19.43 | 601.11K |
| Aug 25, 2026 | $19.48 | $19.70 | $19.30 | $19.54 | 557.78K |
| Aug 24, 2026 | $20.00 | $20.30 | $19.42 | $19.47 | 699.83K |
| Aug 21, 2026 | $19.47 | $20.05 | $19.27 | $19.96 | 1.29M |
| Aug 20, 2026 | $19.66 | $19.745 | $19.105 | $19.48 | 518.04K |
| Aug 19, 2026 | $19.14 | $19.92 | $19.14 | $19.91 | 436.39K |
| Aug 18, 2026 | $18.86 | $19.42 | $18.86 | $19.14 | 499.05K |
| Aug 17, 2026 | $18.82 | $18.86 | $18.49 | $18.69 | 481.55K |
| Aug 14, 2026 | $19.01 | $19.07 | $18.70 | $18.93 | 206.75K |
| Aug 13, 2026 | $19.21 | $19.31 | $18.83 | $18.95 | 246.71K |
| Aug 12, 2026 | $18.57 | $19.13 | $18.39 | $19.00 | 329.28K |
| Aug 11, 2026 | $18.675 | $19.23 | $18.675 | $18.80 | 416.04K |
| Aug 10, 2026 | $18.50 | $19.15 | $18.50 | $18.84 | 349.5K |
The latest Smart Investors Daily articles mentioning SIBN.
SIBN research
Company profile and research snapshot.
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 4, 2026 | TD Cowen | Buy | — |
| Aug 4, 2026 | UBS | Buy | — |
| Aug 4, 2026 | Truist Securities | Buy | — |
| Jul 28, 2026 | UBS | Buy | — |
| Jul 16, 2026 | Truist Securities | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 4, 2026
UBS analyst Patrick Wood maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $24 to $25.
Benzinga · Aug 4, 2026
Truist Securities analyst Richard Newitter reiterates SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $21 to $23.
Benzinga · Aug 4, 2026
TD Cowen analyst Mathew Blackman maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $18 to $20.
SeekingAlpha · Aug 4, 2026
SI-BONE, Inc. (SIBN) Q2 2026 Earnings Call August 3, 2026 4:30 PM EDTCompany ParticipantsSaqib Iqbal - Vice President of Financial Planning & Analysis...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning SIBN.